Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort
Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and b...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
BioMed Central
2017
|
| _version_ | 1826286498999173120 |
|---|---|
| author | Fortner, RT Sarink, D Schock, H Johnson, T Tjønneland, A Olsen, A Overvad, K Affret, A His, M Boutron-Ruault, MC Boeing, H Trichopoulou, A Naska, A Orfanos, P Palli, D Sieri, S Mattiello, A Tumino, R Ricceri, F Bueno-de-Mesquita, HB Peeters, PH Van Gils, CH Weiderpass, E Lund, E Quirós, JR Agudo, A Sánchez, MJ Chirlaque, MD Ardanaz, E Dorronsoro, M Key, T Khaw, KT Rinaldi, S Dossus, L Gunter, M Merritt, MA Riboli, E Kaaks, R |
| author_facet | Fortner, RT Sarink, D Schock, H Johnson, T Tjønneland, A Olsen, A Overvad, K Affret, A His, M Boutron-Ruault, MC Boeing, H Trichopoulou, A Naska, A Orfanos, P Palli, D Sieri, S Mattiello, A Tumino, R Ricceri, F Bueno-de-Mesquita, HB Peeters, PH Van Gils, CH Weiderpass, E Lund, E Quirós, JR Agudo, A Sánchez, MJ Chirlaque, MD Ardanaz, E Dorronsoro, M Key, T Khaw, KT Rinaldi, S Dossus, L Gunter, M Merritt, MA Riboli, E Kaaks, R |
| author_sort | Fortner, RT |
| collection | OXFORD |
| description | Circulating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.The associations between OPG and ER+ and ER- breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER- breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p trend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER- disease did not differ by menopausal status at blood collection (p het = 0.97), and we observed no heterogeneity by HT use at blood collection (p het ≥ 0.43) or age at breast cancer diagnosis (p het ≥ 0.30).This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER- breast cancer. |
| first_indexed | 2024-03-07T01:44:40Z |
| format | Journal article |
| id | oxford-uuid:9800c77c-44ef-418a-a7ab-6453f532b6aa |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T01:44:40Z |
| publishDate | 2017 |
| publisher | BioMed Central |
| record_format | dspace |
| spelling | oxford-uuid:9800c77c-44ef-418a-a7ab-6453f532b6aa2022-03-27T00:04:08ZOsteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohortJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:9800c77c-44ef-418a-a7ab-6453f532b6aaEnglishSymplectic Elements at OxfordBioMed Central2017Fortner, RTSarink, DSchock, HJohnson, TTjønneland, AOlsen, AOvervad, KAffret, AHis, MBoutron-Ruault, MCBoeing, HTrichopoulou, ANaska, AOrfanos, PPalli, DSieri, SMattiello, ATumino, RRicceri, FBueno-de-Mesquita, HBPeeters, PHVan Gils, CHWeiderpass, ELund, EQuirós, JRAgudo, ASánchez, MJChirlaque, MDArdanaz, EDorronsoro, MKey, TKhaw, KTRinaldi, SDossus, LGunter, MMerritt, MARiboli, EKaaks, RCirculating osteoprotegerin (OPG), a member of the receptor activator of nuclear factor kappa-B (RANK) axis, may influence breast cancer risk via its role as the decoy receptor for both the RANK ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Circulating OPG and breast cancer risk has been examined in only one prior study.A case-control study was nested in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A total of 2008 incident invasive breast cancer cases (estrogen receptor (ER)+, n = 1622; ER-, n = 386), matched 1:1 to controls, were included in the analysis. Women were predominantly postmenopausal at blood collection (77%); postmenopausal women included users and non-users of postmenopausal hormone therapy (HT). Serum OPG was quantified with an electrochemiluminescence assay. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated using conditional logistic regression.The associations between OPG and ER+ and ER- breast cancer differed significantly. Higher concentrations of OPG were associated with increased risk of ER- breast cancer (top vs. bottom tertile RR = 1.93 [95% CI 1.24-3.02]; p trend = 0.03). We observed a suggestive inverse association for ER+ disease overall and among women premenopausal at blood collection. Results for ER- disease did not differ by menopausal status at blood collection (p het = 0.97), and we observed no heterogeneity by HT use at blood collection (p het ≥ 0.43) or age at breast cancer diagnosis (p het ≥ 0.30).This study provides the first prospective data on OPG and breast cancer risk by hormone receptor subtype. High circulating OPG may represent a novel risk factor for ER- breast cancer. |
| spellingShingle | Fortner, RT Sarink, D Schock, H Johnson, T Tjønneland, A Olsen, A Overvad, K Affret, A His, M Boutron-Ruault, MC Boeing, H Trichopoulou, A Naska, A Orfanos, P Palli, D Sieri, S Mattiello, A Tumino, R Ricceri, F Bueno-de-Mesquita, HB Peeters, PH Van Gils, CH Weiderpass, E Lund, E Quirós, JR Agudo, A Sánchez, MJ Chirlaque, MD Ardanaz, E Dorronsoro, M Key, T Khaw, KT Rinaldi, S Dossus, L Gunter, M Merritt, MA Riboli, E Kaaks, R Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| title | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| title_full | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| title_fullStr | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| title_full_unstemmed | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| title_short | Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort |
| title_sort | osteoprotegerin and breast cancer risk by hormone receptor subtype a nested case control study in the epic cohort |
| work_keys_str_mv | AT fortnerrt osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT sarinkd osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT schockh osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT johnsont osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT tjønnelanda osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT olsena osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT overvadk osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT affreta osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT hism osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT boutronruaultmc osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT boeingh osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT trichopouloua osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT naskaa osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT orfanosp osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT pallid osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT sieris osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT mattielloa osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT tuminor osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT riccerif osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT buenodemesquitahb osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT peetersph osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT vangilsch osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT weiderpasse osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT lunde osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT quirosjr osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT agudoa osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT sanchezmj osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT chirlaquemd osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT ardanaze osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT dorronsorom osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT keyt osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT khawkt osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT rinaldis osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT dossusl osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT gunterm osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT merrittma osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT ribolie osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort AT kaaksr osteoprotegerinandbreastcancerriskbyhormonereceptorsubtypeanestedcasecontrolstudyintheepiccohort |